Dimensional Fund Advisors’s Processa Pharmaceuticals PCSA Stock Holding History

Dimensional Fund Advisors’s Portfolio PCSA Stock Details PCSA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	$28K	Buy	+25	New	+$36.8K	﹤0.01%	3451

Other funds holding PCSA

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACM

AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return

WVP

Worth Venture Partners Fort Lee, New Jersey $44.3M AUM 34.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

VCA

Verdence Capital Advisors Hunt Valley, Maryland $1.9B AUM 36.41% 1-Year Est. Return

CBA

Coastal Bridge Advisors Westport, Connecticut $1.62B AUM 36.83% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Janney Montgomery Scott Philadelphia, Pennsylvania $51.6B AUM 27.34% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dimensional Fund Advisors's PCSA Position: Q3 2022 in Review

Dimensional Fund Advisors opened a new position in Processa Pharmaceuticals (PCSA) in Q3 2022: 25 shares worth $28K. The stake represents ﹤0.01% of the portfolio and ranks #3451 among its holdings.

18 funds tracked by Wall St. Rank hold PCSA as of Q3 2022.

Dimensional Fund Advisors held 25 shares of Processa Pharmaceuticals worth $28K as of Q3 2022.
Processa Pharmaceuticals was a new Dimensional Fund Advisors position in Q3 2022.
Processa Pharmaceuticals made up ﹤0.01% of Dimensional Fund Advisors's portfolio in Q3 2022, its #3451 holding.
18 funds tracked by Wall St. Rank held Processa Pharmaceuticals as of Q3 2022.

Based on Dimensional Fund Advisors's 13F filing for Q3 2022, filed 10 Nov 2022.